CytoDyn Releases ESMO Breast Cancer Meeting Poster

Core Insights - CytoDyn Inc. is a biotechnology company focused on developing leronlimab, a CCR5 antagonist with potential applications in multiple therapeutic areas, including oncology, infectious diseases, and autoimmune conditions [2] Group 1: Company Developments - CytoDyn presented a poster at the European Society for Medical Oncology's Breast Cancer meeting, highlighting the novel mechanism of action of leronlimab for treating solid tumors [1] - The poster presentation took place from May 14-17, 2025, in Munich, Germany [1] - Additional information regarding the data presented at ESMO was released in a press release on May 13, 2025 [1] Group 2: Product Information - Leronlimab is an investigational humanized IgG4 monoclonal antibody designed to bind to CCR5, a protein on immune system cells involved in various disease processes [2] - The company has explored the use of leronlimab across multiple therapeutic areas, indicating its versatility and potential in treating different conditions [2]